在ROS1-阳性高级非小细胞肺癌中对crizotinib的异常长期反应
Anjali Murali1, Anju Farsana A1, Sobha Subramaniam2
1Department of Medical Oncology, Amrita Institute of Medical Science and Research Centre Amrita Vishwa Vidyapeetham Kochi India.
Respirology case reports
|September 25, 2024
概括
本案例研究显示,一名患有晚期非小细胞肺癌 (NSCLC) 的患者对ROS1阳性NSCLC的向疗法crizotinib有显著的反应,持续超过94个月.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球最常见的肺癌类型.
- 一个小组的NSCLC患者呈现可操作的瘤原体变化,包括ROS1重组.
- 识别这些变化对于有效的治疗策略至关重要.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.0K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
